- ￥4960
- MedChemExpress(MCE)
- 美国
- HY-114456
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C, protect from light
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- 规格：
1 mg
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Ganglioside GM3
CAS No. : 124579-05-1
MCE 国际站：Ganglioside GM3
产品活性：Ganglioside GM3 是 a、b 和 c 系列神经节苷的前体，与表皮生长因子和胰岛素受体等跨膜受体相互作用，通过创造专门的脂质环境调节受体功能。Ganglioside GM3 由 GM3 合成酶合成，可用于高胆固醇血症的研究。
研究领域：Others
作用靶点：Others
In Vitro: Ganglioside GM3, produced by addition of sialic acid to LacCer, is expressed mainly in adipose tissue and muscle in humans and mice, and liver and serum in humans. GM3 expression in adipocytes is induced by stimulation of the inflammatory cytokines TNF-α and IL-1β, derived from tissue macrophages.
相关产品：Bioactive Compound Library Plus | Digitonin | 5-Ph-IAA | FLAG peptide | Tocofersolan | Monocrotaline | Lactate sodium | TCEP hydrochloride | 3X FLAG peptide | DPPH | Pertussis Toxin | Pronase E (Activity ≥ 7000 U/g) | O-Propargyl-Puromycin | NMDI14 | Phytohemagglutinin | MYLS22 | Hyaluronidase | Biotinyl tyramide | Kifunensine | Human IgG1 kappa, Isotype Control | 4-Azido-L-phenylalanine | 6-Aminonicotinamide | Ammonium tetrathiomolybdate(VI) | OVA Peptide(257-264) TFA | Alkyne-phenol | Lauryl maltose neopentyl glycol | SHIN1 | CHAPS | Cytosporone B
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验含有唾液酸的鞘脂类。克伦克（E.Klenk，1935）首先发现在患Tay－sachs病（泰萨氏幼年型黑白痴病）的小儿脑中有蓄积（Tag－Sachs gangli-oside），在脑灰白质中含量很多，所以对这类糖脂命名为神经节苷脂。已知糖部分是由己糖、氨基糖、唾液酸组成的脑神经节苷脂有8种以上。由山川民夫（1951）在马血球基质中找到的非神经系统的神经节苷脂——主要是血苷脂[hematoside，结构为神经酰胺（1←1β）GLc（4←1β）Gal（3←2α）唾液酸]。神经节苷脂较多地存在
Immunohistochemistry using Anti-Ganglioside Antibodies
Immunohistochemistry using Anti-Ganglioside Antibodies Tadashi Tai~Head, Department of Tumor Immunology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan An indirect method using immuno- fluorescence coupled
Tumor reactive monoclonal antibodies (mAb) have been developed and tested as anti-tumor therapy. Some mAb have shown efficacy and are now approved as clinical cancer therapy. The mechanism of action for the antitumor effect includes tumor
技术资料暂无技术资料 索取技术资料
